Source comparison
Thymosin Alpha-1 Chronic Infection Research: Study Design Comparison
Chronic Hepatitis B 1.6 mg subcutaneous 2x/week HBeAg seroconversion rate, viral load reduction 24–48 weeks Tα1 shows consistent 20–35% improvement in seroconversion vs controls. Effect correlates with baseline CD4+ count Chronic Hepatitis C (genotype 1) 1.6 m
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B
- 1.6 mg subcutaneous 2x/week
- HBeAg seroconversion rate, viral load reduction
- 24–48 weeks
- Tα1 shows consistent 20–35% improvement in seroconversion vs controls. Effect correlates with baseline CD4+ count
- Chronic Hepatitis C (genotype 1)
- 1.6 mg subcutaneous 2x/week + pegIFN-α
- Sustained virological response (SVR) at 24 weeks post-treatment
- 48-week treatment + 24-week follow-up
- Combination therapy increases SVR by 15–18% vs pegIFN alone in treatment-naive patients. No benefit in relapsers
- HIV latency reversal models
- 3.2–6.4 mg subcutaneous weekly
- CD8+ T-cell cytotoxic activity, viral rebound kinetics
- 8–16 weeks
- Preliminary data shows modest CD8+ activation but insufficient to achieve functional cure. Useful as adjuvant, not monotherapy
- Tuberculosis (latent TB reactivation models)
- 1.6 mg subcutaneous 3x/week
- IFN-γ release assay response, granuloma containment
- 12–24 weeks
- Mixed results. Effective in models with intact T-cell memory, ineffective in severely immunocompromised models
- Candida albicans (recurrent mucosal)
- 0.8–1.6 mg subcutaneous 2x/week
- Th17 cell differentiation, neutrophil recruitment
- 4–8 weeks
- Limited efficacy. Tα1 drives Th1 responses but mucosal candidiasis requires Th17, which Tα1 doesn't preferentially induce